ArticleBlood cancer journal2022

Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib.

Patrick Harrington et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.